Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 21;18(7):1587.
doi: 10.3390/ijms18071587.

Human Chorionic Gonadotropin and Breast Cancer

Affiliations
Review

Human Chorionic Gonadotropin and Breast Cancer

Susanne Schüler-Toprak et al. Int J Mol Sci. .

Abstract

Breast cancer is well known as a malignancy being strongly influenced by female steroids. Pregnancy is a protective factor against breast cancer. Human chorionic gonadotropin (HCG) is a candidate hormone which could mediate this antitumoral effect of pregnancy. For this review article, all original research articles on the role of HCG in breast cancer were considered, which are listed in PubMed database and were written in English. The role of HCG in breast cancer seems to be a paradox. Placental heterodimeric HCG acts as a protective agent by imprinting a permanent genomic signature of the mammary gland determining a refractory condition to malignant transformation which is characterized by cellular differentiation, apoptosis and growth inhibition. On the other hand, ectopic expression of β-HCG in various cancer entities is associated with poor prognosis due to its tumor-promoting function. Placental HCG and ectopically expressed β-HCG exert opposite effects on breast tumorigenesis. Therefore, mimicking pregnancy by treatment with HCG is suggested as a strategy for breast cancer prevention, whereas targeting β-HCG expressing tumor cells seems to be an option for breast cancer therapy.

Keywords: breast cancer; human chorionic gonadotropin; pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. McGuire W.L. Estrogen receptors in human breast cancer. J. Clin. Investig. 1973;52:73–77. doi: 10.1172/JCI107175. - DOI - PMC - PubMed
    1. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002;94:606–616. - PubMed
    1. Wang M., Wu X., Chai F., Zhang Y., Jiang J. Plasma prolactin and breast cancer risk: A meta-analysis. Sci. Rep. 2016;6:25998. doi: 10.1038/srep25998. - DOI - PMC - PubMed
    1. Agrawal B., Reddish M.A., Krantz M.J., Longenecker B.M. Does pregnancy immunize against breast cancer? Cancer Res. 1995;55:2257–2261. - PubMed

Substances